# APEPTICO Forschung und Entwicklung

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apeptico-forschung-und-entwicklung

- Industry: Biotechnology
- Headquarters: Vienna, Austria
- Website: www.apeptico.com
- Total disclosed funding: $1.4M
- Latest round: Seed (May 29, 2009)
- Investors on record: 1

## About

APEPTICO Forschung und Entwicklung GmbH develops innovative peptide-based drugs, with a focus on treating pulmonary conditions and acute respiratory distress syndrome through its core product, solnatide (AP301).Founded in 2008, APEPTICO Forschung und Entwicklung GmbH is based in Vienna, Austria. The company focuses on developing peptide-based therapeutics, particularly solnatide, for treating pulmonary edema and ARDS. CEO Bernhard Fischer has a background in the biotech industry, although specific details on prior ventures are not available. The company was involved in 5 deals, with the most recent occurring on July 8, 2013, when they received a Grant of EUR 0.50 mn from the Austrian Research Promotion Agency, contributing to a total amount raised of EUR 2.00 mn.APEPTICO Forschung und Entwicklung GmbH specializes in developing innovative peptide-based drugs, prominently featuring solnatide (AP301), which targets pulmonary edema and ARDS. Solnatide operates by activating the epithelial sodium channel (ENaC), facilitating the restoration of barrier function essential for patients suffering from conditions like COVID-19. The company primarily markets its products in Europe, collaborating with healthcare institutions and research organizations, and engaging directly with hospitals for clinical trials and compassionate use programs.APEPTICO generates revenue through partnerships with medical institutions and research organizations, facilitating clinical evaluations and eventual commercialization of products. Revenue streams include agreements for clinical trials, R&D collaborations, and projected future sales of solnatide to healthcare providers. Licensing agreements and potential subscription models for research access are also part of their revenue strategy, with pricing aligned to the specific needs of their partners and tied to successful clinical outcomes.Moving forward, APEPTICO plans to expand its product line and market reach. The recent Grant received in July 2013 will be allocated towards further clinical research and development of solnatide and upcoming innovative therapeutics. The company aims to enter new European markets and strengthen its presence in existing ones by the end of 2023, while also exploring potential collaborations with additional healthcare providers to enhance its commercialization efforts.

## Funding rounds

- Seed, May 29, 2009, $1.4M — BioScience Ventures Group

## Investors

- BioScience Ventures Group (https://capitalatlas.ai/funds/bioscience-ventures-group) — Seed